Standout Papers

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera 2021 2026 2022 2024329
  1. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera (2021)
    Alexander Muik, Ann-Kathrin Wallisch et al. Science
  2. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma (2021)
    Uğur Şahin, Ö. Türeci et al. Annals of Oncology

Immediate Impact

5 by Nobel laureates 22 from Science/Nature 78 standout
Sub-graph 1 of 21

Citing Papers

Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
Spike deep mutational scanning helps predict success of SARS-CoV-2 clades
2024 StandoutNature
2 intermediate papers

Works of Daniel Maurus being referenced

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
2021 StandoutScience
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
2019

Author Peers

Author Last Decade Papers Cites
Daniel Maurus 265 221 164 311 9 819
Sayuri Masuda 106 261 286 97 9 940
Nathalie Castéran 127 140 19 31 13 813
C A Parkos 60 82 91 24 8 946
Tyler Caron 65 192 133 17 13 749
Julien Maurizio 70 153 42 56 10 890
Martina Di Modica 86 425 8 79 15 904
Rebecca Leyland 45 138 17 51 11 737
Lisa T.C. Vogelpoel 31 207 27 62 8 853
Kelly L. Singel 71 196 20 58 18 762
Aurélien Sarde 64 283 45 40 12 911

All Works

Loading papers...

Rankless by CCL
2026